Deshanda Kurniawan Prayoga, Diah Lia Aulifa, Arif Budiman, Jutti Levita, Supat Jiranusornkul
{"title":"Cyanidin and Cyanidin-3-Glucoside Alleviate Peptic Ulcer Disease: Insights from in vitro, and in vivo Studies.","authors":"Deshanda Kurniawan Prayoga, Diah Lia Aulifa, Arif Budiman, Jutti Levita, Supat Jiranusornkul","doi":"10.2147/DDDT.S500645","DOIUrl":null,"url":null,"abstract":"<p><p>Peptic ulcer disease (PUD) remains a significant global health issue, affecting millions despite a decrease in overall prevalence. However, complications continue to persist, with substantial mortality rates in regions like India and China. Current treatments, though effective, have limitations, driving interest in plant-derived therapy. Anthocyanins, including cyanidin and cyanidin-3-glucoside (C3G), are known for their antioxidant and anti-inflammatory properties. This study aims to explore the potential of cyanidin and C3G in alleviating PUD, focusing on their mechanisms of action and therapeutic efficacy in preclinical studies. Articles were searched in Scopus and PubMed databases and filtered for publication from 2014 to 2024, resulting in 89 articles from Scopus and 11 articles from PubMed. The articles were further screened by title, abstract, and full text, resulting in 6 articles. Cyanidin and C3G were described to be able to alleviate PUD by inhibiting the cytokine pro-inflammatory, reducing inflammation in gastric mucosa, and reducing lipid peroxidation in the gastric mucosa. These compounds have proven effective in managing other health problems, including peptic ulcers, but more in-depth exploration in clinical settings is required to confirm therapeutic potential in humans. It is necessary to validate the therapeutic efficacy and safety in human populations. This review provides an overview of preclinical studies of cyanidin and C3G, such as in vitro and in vivo, focusing on mechanism of action or their effectiveness in alleviating peptic ulcers.</p>","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"19 ","pages":"841-856"},"PeriodicalIF":4.7000,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11812437/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Design, Development and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/DDDT.S500645","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
Peptic ulcer disease (PUD) remains a significant global health issue, affecting millions despite a decrease in overall prevalence. However, complications continue to persist, with substantial mortality rates in regions like India and China. Current treatments, though effective, have limitations, driving interest in plant-derived therapy. Anthocyanins, including cyanidin and cyanidin-3-glucoside (C3G), are known for their antioxidant and anti-inflammatory properties. This study aims to explore the potential of cyanidin and C3G in alleviating PUD, focusing on their mechanisms of action and therapeutic efficacy in preclinical studies. Articles were searched in Scopus and PubMed databases and filtered for publication from 2014 to 2024, resulting in 89 articles from Scopus and 11 articles from PubMed. The articles were further screened by title, abstract, and full text, resulting in 6 articles. Cyanidin and C3G were described to be able to alleviate PUD by inhibiting the cytokine pro-inflammatory, reducing inflammation in gastric mucosa, and reducing lipid peroxidation in the gastric mucosa. These compounds have proven effective in managing other health problems, including peptic ulcers, but more in-depth exploration in clinical settings is required to confirm therapeutic potential in humans. It is necessary to validate the therapeutic efficacy and safety in human populations. This review provides an overview of preclinical studies of cyanidin and C3G, such as in vitro and in vivo, focusing on mechanism of action or their effectiveness in alleviating peptic ulcers.
期刊介绍：
Drug Design, Development and Therapy is an international, peer-reviewed, open access journal that spans the spectrum of drug design, discovery and development through to clinical applications.
The journal is characterized by the rapid reporting of high-quality original research, reviews, expert opinions, commentary and clinical studies in all therapeutic areas.
Specific topics covered by the journal include:
Drug target identification and validation
Phenotypic screening and target deconvolution
Biochemical analyses of drug targets and their pathways
New methods or relevant applications in molecular/drug design and computer-aided drug discovery*
Design, synthesis, and biological evaluation of novel biologically active compounds (including diagnostics or chemical probes)
Structural or molecular biological studies elucidating molecular recognition processes
Fragment-based drug discovery
Pharmaceutical/red biotechnology
Isolation, structural characterization, (bio)synthesis, bioengineering and pharmacological evaluation of natural products**
Distribution, pharmacokinetics and metabolic transformations of drugs or biologically active compounds in drug development
Drug delivery and formulation (design and characterization of dosage forms, release mechanisms and in vivo testing)
Preclinical development studies
Translational animal models
Mechanisms of action and signalling pathways
Toxicology
Gene therapy, cell therapy and immunotherapy
Personalized medicine and pharmacogenomics
Clinical drug evaluation
Patient safety and sustained use of medicines.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
